Atossa Nabs $6.6M
Luke Timmerman6/27/11
Seattle-based Atossa Genetics, the developer of a new diagnostic test for breast cancer, said today it has raised $6.6 million in a private financing. The company, led by former Nastech Pharmaceuticals CEO Steven Quay, said it plans to use the money to introduce its new product in the Northwest, hire a sales force, and develop a next-generation form of the technology. Atossa, which was profiled here a year ago, at one point sought to raise $15 million through an initial public offering.
Pingback: Atossa Genetics Completes $6.6 Million Over-Subscribed Private Placement – Marketwire (press release) | The Cancer Post
Pingback: Seattle company to launch new breast-cancer-risk test – The Seattle Times | The Cancer Post